133 related articles for article (PubMed ID: 37293764)
1. An updated patent review of Mcl-1 inhibitors (2020-2022).
Liu J; Yin F; Wang Z; Song T; Zhang Z
Expert Opin Ther Pat; 2023; 33(5):371-383. PubMed ID: 37293764
[TBL] [Abstract][Full Text] [Related]
2. Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins.
Pal P; Zhang P; Poddar SK; Zheng G
Expert Opin Ther Pat; 2022 Sep; 32(9):1003-1026. PubMed ID: 35993382
[TBL] [Abstract][Full Text] [Related]
3. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
[TBL] [Abstract][Full Text] [Related]
4. MCL-1 inhibitors - where are we now (2019)?
Fletcher S
Expert Opin Ther Pat; 2019 Nov; 29(11):909-919. PubMed ID: 31566022
[No Abstract] [Full Text] [Related]
5. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
[TBL] [Abstract][Full Text] [Related]
6. Mcl-1 inhibitors: a patent review.
Chen L; Fletcher S
Expert Opin Ther Pat; 2017 Feb; 27(2):163-178. PubMed ID: 27744724
[TBL] [Abstract][Full Text] [Related]
7. Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling.
Grundy M; Seedhouse C; Jones T; Elmi L; Hall M; Graham A; Russell N; Pallis M
PLoS One; 2018; 13(1):e0190682. PubMed ID: 29298347
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present).
Fan Y; Hou X; Fang H
Recent Pat Anticancer Drug Discov; 2020; 15(4):306-320. PubMed ID: 32938354
[TBL] [Abstract][Full Text] [Related]
10. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides.
Modi V; Sankararamakrishnan R
J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820
[TBL] [Abstract][Full Text] [Related]
11. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
[TBL] [Abstract][Full Text] [Related]
12. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
[TBL] [Abstract][Full Text] [Related]
13. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
[TBL] [Abstract][Full Text] [Related]
14. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
Ewald L; Dittmann J; Vogler M; Fulda S
Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor receptor inhibitor erdafitinib promotes Mcl-1 degradation and synergistically induces apoptosis with Bcl-xL/Bcl-2 inhibitor in urothelial cancer cells.
Ohtsu A; Arai S; Sawada T; Kato M; Maeno Y; Miyazawa Y; Fujizuka Y; Sekine Y; Koike H; Matsui H; Suzuki K
Biochem Biophys Res Commun; 2022 Nov; 628():76-83. PubMed ID: 36084554
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of aurora kinases and Bcl-xL induces apoptosis through select BH3-only proteins.
Li J; Chen CH; O'Neill KL; Fousek-Schuller VJ; Black AR; Black JD; Zhang J; Luo X
J Biol Chem; 2023 Feb; 299(2):102875. PubMed ID: 36621626
[TBL] [Abstract][Full Text] [Related]
17. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
[TBL] [Abstract][Full Text] [Related]
18. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
[TBL] [Abstract][Full Text] [Related]
19. Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy.
Zhu PJ; Yu ZZ; You QD; Jiang ZY
Drug Discov Today; 2020 Oct; 25(10):1873-1882. PubMed ID: 32771436
[TBL] [Abstract][Full Text] [Related]
20. Targeting MCL-1 in cancer: current status and perspectives.
Wang H; Guo M; Wei H; Chen Y
J Hematol Oncol; 2021 Apr; 14(1):67. PubMed ID: 33883020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
